Compounded Dual-Incretin Formulation / Glycine
Compounded dual GIP / GLP-1 agonist with Glycine
- Format
- Injectable
- Spec
- Multiple concentrations
- Sourcing
- FDA-registered 503A pharmacy
Research Summary
Mechanism & Physiological Role
Glycine-buffered compounded dual-incretin formulation. Same receptor pharmacology as tirzepatide.
Clinical & Research Applications
Discussed in the peer-reviewed literature in the context of weight management and dual-incretin metabolic research. 503A compounded formulations are prepared per individual patient prescriptions.
Scientific Publications
Peer-Reviewed References
This compound's citation set is being curated. Publications will be added after review by our M.Sc. organic chemistry team. Practitioners can request the current sourcing dossier and analytical documentation directly.
Request research dossier ›All compounded formulations are prepared by a licensed 503A sterile compounding pharmacy partner. Compounds are available to NPI-verified licensed practitioners only, per individual patient prescriptions in accordance with applicable state and federal law. Compounded medications are not FDA-approved. Pricing available upon verified account approval.
Ready to add Compounded Dual-Incretin Formulation / Glycine to your protocol?
Compounded formulations are dispensed by our licensed 503A pharmacy partner OBPRx under a valid patient-specific prescription. Prefer a formal quote? Request formulation-specific pricing instead.